Pigment epithelium-derived factor prevents melanoma growth via angiogenesis inhibition

Current Pharmaceutical Design

Volumn 14, Issue 36, 2008, Pages 3802-3809

  Abe, Riichiro ^a   Fujita, Yasuyuki ^a   Yamagishi, Sho Ichi ^b   Shimizu, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MICROSOMAL AMINOPEPTIDASE; PIGMENT EPITHELIUM DERIVED FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; RAS PROTEIN; SCATTER FACTOR; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER GROWTH; CANCER INHIBITION; DNA DAMAGE; DOWN REGULATION; EXPRESSION VECTOR; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOMA; METASTASIS POTENTIAL; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SUBRETINAL NEOVASCULARIZATION; SURVIVAL RATE; UPREGULATION; APOPTOSIS; CELL DIVISION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CELL DIVISION; EYE PROTEINS; HUMANS; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; SERPINS;

EID: 61449159054     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786898626     Document Type: Review

References (71)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365: 687-701.
2. Balch CM, Soong S-J, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001; 19: 3622-34.
3. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-53.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249.
5. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20: 3906-27.
6. Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 2000; 60: 4932-8.
7. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 2002; 98: 682-9.
8. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-60.
9. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003; 22: 3172-9.
10. Mihm MC Jr, Clark WH Jr, Reed RJ. The clinical diagnosis of malignant melanoma. Semin Oncol 1975; 2: 105-18.
11. Erhard H, Rietveld FJ, van Altena MC, Brocker EB, Ruiter DJ, de Waal RM. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res 1997; 7(Suppl 2): S19-26.
12. Marcoval J, Moreno A, Graells J, Vidal A, Escriba JM, Garcia-Ramirez M, et al. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 1997; 24: 212-8.
13. Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol 1988; 133: 419-23.
14. Vlaykova T, Laurila P, Muhonen T, Hahka-Kemppinen M, Jekunen A, Alitalo K, et al. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res 1999; 9: 59-68.
15. Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR, 3rd. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 2002; 20: 1826-31.
16. Ferrara N. Vascular endothelial growth factor: Molecular and biological aspects. Curr Top Microbiol Immunol 1999; 237: 1-30.
17. Detmar M. Molecular regulation of angiogenesis in the skin. J Invest Dermatol 1996; 106: 207-8.
18. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997; 76: 930-4.
19. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.
20. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 2000; 115: 1000-7.
21. Roodink I, van der Laak J, Kusters B, Wesseling P, Verrijp K, de Waal R, et al. Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression. Int J Cancer 2006; 119: 2054-62.
22. Loffek S, Zigrino P, Steiger J, Kurschat P, Smola H, Mauch C. Melanoma cell-derived vascular endothelial growth factor induces endothelial tubulogenesis within fibrin gels by a metalloproteinase-mediated mechanism. Eur J Cell Biol In Press, Corrected Proof.
23. Reed JA, McNutt NS, Albino AP. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Am J Pathol 1994; 144: 329-36.
24. Dreau D, Foster M, Hogg M, Swiggett J, Holder WD, White RL. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma. Oncol Res 2000; 12: 241-51.
25. Menrad A, Speicher D, Wacker J, Herlyn M. Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res 1993; 53: 1450-5.
26. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, et al. Aminopeptidase N Is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60: 722-7.
27. Shim JS, Kim JH, Cho HY, Yum YN, Kim SH, Park H-J, et al. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol 2003; 10: 695.
28. Bhagwat SV, Petrovic N, Okamoto Y, Shapiro LH. The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. Blood 2003; 101: 1818-26.
29. Fontijn D, Duyndam MC, van Berkel MP, Yuana Y, Shapiro LH, Pinedo HM, et al. CD13/Aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells. Br J Cancer 2006; 94: 1627-36.
30. Sato Y. Aminopeptidases and angiogenesis. Endothelium 2003; 10: 287-90.
31. Nurnberg W, Tobias D, Otto F, Henz BM, Schadendorf D. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol 1999; 189: 546-51.
32. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19: 577-83.
33. Barnhill RL, Xiao M, Graves D, Antoniades HN. Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGFalpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Br J Dermatol 1996; 135: 898-904.
34. Grant SW, Kyshtoobayeva AS, Kurosaki T, Jakowatz J, Fruehauf JP. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. Cancer Detect Prev 1998; 22: 185-94.
35. Gitay-Goren H, Halaban R, Neufeld G. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 1993; 190: 702-8.
36. Potgens AJ, Lubsen NH, van Altena MC, Schoenmakers JG, Ruiter DJ, de Waal RM. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 1995; 146: 197-209.
37. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ, et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56: 172-81.
38. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000; 12: 547-54.
39. Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S, Schmiegel W. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res 2001; 61: 7282-90.
40. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor [alpha] antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotech 2000; 18: 1185.
41. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells upregulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997; 151: 1105-13.
42. Rofstad EK, Halsor EF. Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: Involvement of microvascular hot spots induced in hypoxic foci by interleukin 8. Br J Cancer 2002; 86: 301-8.
43. Forsberg K, Valyi-Nagy I, Heldin C, Herlyn M, Westermark B. Platelet-Derived Growth Factor (PDGF) in oncogenesis: Development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. PNAS 1993; 90: 393-7.
44. Tombran-Tink J, Chader GG, Johnson LV. PEDF: A pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991; 53: 411-4.
45. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999; 285: 245-8.
46. Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K, et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002; 43: 821-9.
47. Spranger J, Osterhoff M, Reimann M, Mohlig M, Ristow M, Francis MK, et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001; 50: 2641-5.
48. Coljee VW, Rotenberg MO, Tresini M, Francis MK, Cristofalo VJ, Sell C. Regulation of EPC-1/PEDF in normal human fibroblasts is posttranscriptional. J Cell Biochem 2000; 79: 442-52.
49. Abramson LP, Stellmach V, Doll JA, Cornwell M, Arensman RM, Crawford SE. Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model. J Pediatric Surg 2003; 38: 336.
50. Crawford SE, Stellmach V, Ranalli M, Huang X, Huang L, Volpert O, et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: A multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 2001; 114: 4421-8.
51. Guan M, Pang CP, Yam HF, Cheung KF, Liu WW, Lu Y. Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther 2004; 11: 325-32.
52. Doll JA, Stellmach VM, Bouck NP, Bergh ARJ, Lee C, Abramson LP, et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003; 9: 774.
53. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999; 100: 1423-31.
54. Abe R, Shimizu T, Yamagishi S-i, Shibaki A, Amano S, Inagaki Y, et al. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol 2004; 164: 1225-32.
55. Wang L, Schmitz V, Perez-Mediavilla A, Izal I, Prieto J, Qian C. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther 2003; 8: 72-9.
56. Mahtabifard A, Merritt RE, Yamada RE, Crystal RG, Korst RJ. In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies. J Thorac Cardiovasc Surg 2003; 126: 28-38.
57. Auricchio A, Behling KC, Maguire AM, O'Connor EM, Bennett J, Wilson JM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 2002; 6: 490-4.
58. Kyoko Ohno-Matsui IMJT-TDMMOTUMHS-iMMM. Novel mechanism for age-related macular degeneration: An equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 2001; 189: 323-33.
59. Duh EJ, Yang HS, Haller JA, De Juan E, Humayun MS, Gehlbach P, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: Implications for ocular angiogenesis. Am J Ophthalmol 2004; 137: 668-74.
60. Ohno-Matsui K, Yoshida T, Uetama T, Mochizuki M, Morita I. Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun 2003; 303: 962-7.
61. Tombran-Tink J, Barnstable CJ. Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: Possible mediators of angiogenesis and matrix remodeling in the bone. Biochem Biophys Res Commun 2004; 316: 573-9.
62. Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun 2002; 296: 877-82.
63. Cao W, Tombran-Tink J, Chen W, Mrazek D, Elias R, McGinnis JF. Pigment epithelium-derived factor protects cultured retinal neurons against hydrogen peroxide-induced cell death. J Neurosci Res 1999; 57: 789-800.
64. Jimenez-Cervantes C, Martinez-Esparza M, Perez C, Daum N, Solano F, Garcia-Borron JC. Inhibition of melanogenesis in response to oxidative stress: Transient downregulation of melanocyte differentiation markers and possible involvement of microphthalmia transcription factor. J Cell Sci 2001; 114: 2335-44.
65. Rodolfo M, Cato EM, Soldati S, Ceruti R, Asioli M, Scanziani E, et al. Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy. Cancer Gene Ther 2001; 8: 491-6.
66. Scappaticci FA, Contreras A, Smith R, Bonhoure L, Lum B, Cao Y, et al. Statin-AE: A novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity. Angiogenesis 2001; 4: 263-8.
67. Gao G, Li Y, Gee S, Dudley A, Fant J, Crosson C, et al. Downregulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: A possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 2002; 277: 9492-7.
68. Petersen SV, Valnickova Z, Enghild JJ. Pigment-epithelium-derived factor (PEDF) occurs at a physiologically relevant concentration in human blood: Purification and characterization. Biochem J 2003; 374: 199-206.
69. Yamagishi S-I, Inagaki Y, Nakamura K, Abe R, Shimizu T, Yoshimura A, et al. Pigment epithelium-derived factor inhibits TNF-[alpha]-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol 2004; 37: 497.
70. Matsumoto K, Ishikawa H, Nishimura D, Hamasaki K, Nakao K, Eguchi K. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology 2004; 40: 252-9.
71. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. PNAS 2003; 100: 12917-22.